A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function by Tallkvist, Jonas et al.
  
This is an author produced version of a paper published in 
Cell biology and toxicology. 
This paper has been peer-reviewed and is proof-corrected, but does not 
include the journal pagination. 
Citation for the published paper: 
Tallkvist, Jonas., Yagdiran, Yagmur., Danielsson, Louise., Oskarsson, 
Agneta. (2015) A model of secreting murine mammary epithelial HC11 
cells comprising endogenous Bcrp/Abcg2 expression and function. Cell 
biology and toxicology. Volume: 31, Number: 2, pp 111-120. 
http://dx.doi.org/10.1007/s10565-015-9298-5. 
Access to the published version may require journal subscription. 
Published with permission from: Springer. 
 
Epsilon Open Archive http://epsilon.slu.se 
 1 
 1 
 2 
A Model of Secreting Murine Mammary Epithelial HC11 Cells Comprising Endogenous 3 
Bcrp/Abcg2 Expression and Function 4 
 5 
Jonas Tallkvist
*
, Yagmur Yagdiran, Louise Danielsson, Agneta Oskarsson  6 
 7 
Department of Biomedical Sciences and Veterinary Public Health, Swedish University of 8 
Agricultural Sciences, SE-750 07 Uppsala, Sweden 9 
 10 
 11 
 12 
 13 
 14 
Running title: Bcrp/Abcg2 Mediated Transport in Mammary Epithelial Cells 15 
 16 
 
17 
 
18 
 
19 
*
Corresponding author: 20 
Jonas Tallkvist 21 
Department of Biomedical Sciences and Veterinary Public Health, Swedish University of 22 
Agricultural Sciences, SE-750 07 Uppsala, Sweden 23 
 24 
Phone.: +46 18 673178; Email: Jonas.Tallkvist@slu.se 25 
26 
 2 
Abstract  1 
 2 
Breast cancer resistance protein (Bcrp/Abcg2) and multidrug transporter 1 (Mdr1/Abcb1) are 3 
efflux proteins located in the apical membrane of mammary epithelial cells (MEC). Bcrp is 4 
induced in MEC during gestation and lactation, while Mdr1 is down-regulated during 5 
lactation. Numerous drugs and toxic compounds are known to be actively secreted into milk 6 
by Bcrp, but most chemicals have not been investigated in this respect, emphasizing the need 7 
for functional Bcrp studies in an established cell line with secreting mammary epithelial cells. 8 
The present study was undertaken to examine expressions of Bcrp and Mdr1 in mammary 9 
epithelial HC11 cells, derived from a mid-gestational murine mammary gland. In addition, 10 
Bcrp function was assessed by transport experiments with mitoxantrone (MX) in 11 
undifferentiated HC11 cells, in HC11 cells subjected to Bcrp RNA interference (RNAi) as 12 
well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones. 13 
Differentiated HC11 cells organized into alveolar-resembling structures and gene expression 14 
of the major milk protein -casein was induced, whereas undifferentiated cells formed 15 
monolayers with lower -casein expression. Bcrp and Mdr1 gene and protein were expressed 16 
in both undifferentiated and differentiated HC11 cells. Differentiation of HC11 cells resulted 17 
in increased Bcrp protein expression, while Mdr1 gene and protein expressions were reduced. 18 
The Bcrp inhibitor elacridar (GF120918) reduced secretion and increased accumulation of 19 
MX in both undifferentiated and differentiated HC11 cells. Silencing of the Bcrp gene caused 20 
an increased accumulation of MX. The results indicate that the HC11 cell model provides a 21 
promising tool to investigate transport of potential Bcrp substrates in mammary epithelial 22 
cells. 23 
 24 
 25 
26 
 3 
Introduction 1 
 2 
Breast cancer resistance protein (BCRP/ABCG2) is a 72 kDa protein, composed by a single 3 
N-terminal ATP binding site followed by six putative transmembrane segments, belonging to 4 
the ATP binding cassette (ABC) superfamily of transporters (Doyle et al., 1998). BCRP is 5 
situated in the apical membrane of epithelial cells in numerous tissues including the intestine, 6 
liver, kidneys and several blood-tissue barriers where it serves to extrude its substrates and by 7 
these means limiting availability and systemic exposure (Jonker et al., 2000; Maliepaard et al., 8 
2001; Zhang et al., 2004). Furthermore, BCRP is highly expressed in cancer cells where it 9 
prevents the uptake of the antineoplastic drug mitoxantrone, diminishing its therapeutic effect 10 
(Doyle et al., 1998; Bates et al., 2001). Thus, one important biological function of BCRP in 11 
most tissues appears to comprise cellular protection and detoxification.  12 
 13 
BCRP is also expressed in apical membrane of mammary epithelial cells (MEC) which faces 14 
the alveolar lumen of the mammary glands (Jonker et al., 2005; Lindner et al., 2013). During 15 
gestation and lactation BCRP is upregulated. Although the physiological role for BCRP in 16 
MEC is not totally clarified the transporter has been demonstrated to actively efflux vitamin 17 
B2 (riboflavin) into milk (van Herwaarden et al., 2007; Vlaming et al., 2009).  Furthermore, 18 
active secretion of a variety of exogenous BCRP substrates, including human and veterinary 19 
drugs, environmental pollutants and other food contaminants, into milk have been 20 
demonstrated (Jonker et al., 2005; van Herwaarden et al., 2007; Mealey 2012). Expression 21 
and function of BCRP can also be influenced by chemicals. Thus, flavonoids and 22 
isoflavonoids, present in many food and feed plants, inhibit BCRP and may thus decrease 23 
milk secretion of BCRP substrates (Zhang et al., 2004; Morris and Zhang, 2006). On the other 24 
hand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the fungicide prochloraz induce 25 
 4 
BCRP in mammary epithelial cells and may increase the milk excretion of BCRP substrates 1 
(Halwachs et al., 2013). 2 
 3 
The exposure of hazardous compounds via milk in sensitive population groups is of high 4 
concern in risk assessment and there is a need for methods to screen for chemicals with active 5 
transport into milk and to further investigate the underlying mechanisms. Transfected Madin-6 
Darby Canine Kidney II (MDCKII) epithelial cells stably expressing human, bovine and 7 
caprine BCRP have been used to identify new BCRP substrates as well as the impact of the 8 
common Y581S point mutation in BCRP function (Jonker et al, 2000; Real et al., 2011; 9 
Wassermann et al., 2013; Halwachs et al., 2014). However, expression and function of 10 
endogenous BCRP in non-tumorigenic mammary epithelial cell lines has not yet been 11 
examined. Such a model would be valuable for studies on BCRP expression and function after 12 
treatment with xenobiotics. 13 
 14 
HC11 cells are non-tumorigenic mammary epithelial cells derived from the mouse mammary 15 
epithelial cell line COMMA-1D collected from the mammary glands of Balb/c mice during 16 
mid-gestation (Danielson et al, 1984). The HC11 cells express functional prolactin receptors 17 
and have been used as a model to examine the progression of mammary epithelial 18 
differentiation to a secreting phenotype (Ball et al., 1988; Marte et al., 1994; Desrivières et al., 19 
2003). In addition, the HC11 cell model has been applied to characterize transporters 20 
implicated in the flux of zinc, copper, sodium and calcium across the membranes of the 21 
lactating mammary epithelium (Kelleher and Lönnerdal, 2005, 2006; Boyd and Náray-Fejes-22 
Tóth, 2007; Öhrvik et al, 2010; McCormick and Kelleher, 2012; Ross et al., 2013). However, 23 
no studies have so far been directed to investigating expression and function of ABC 24 
transporters in HC11 cells.  25 
 5 
 1 
The present study was undertaken to examine endogenous expressions of Bcrp and Mdr1 in 2 
mammary epithelial HC11 cells. In addition, transport experiments with the BCRP substrate 3 
mitoxantrone (MX) were carried out in undifferentiated HC11 cells, in HC11 cells subjected 4 
to Bcrp RNAi as well as in HC11 cells stimulated to differentiate by treatment with lactogenic 5 
hormones.6 
 6 
Materials and Methods 1 
 2 
Cells 3 
HC11 cells of passage 26 was a generous gift from Dr Shannon Kelleher, Department of 4 
Nutritional Sciences, Pennsylvania State University, USA and was cultured by permission of 5 
Dr Bernd Groner, Institute for Biomedical Research, Frankfurt, Germany. The cells were 6 
expanded in T75 tissue culture flasks at 37°C in 15 ml of sterile filtered RPMI 1640 medium 7 
containing L-glutamin and 25 mM HEPES (Invitrogen) supplemented with 50 g/ml 8 
gentamicin, 5 g/ml bovine insulin, 10 ng/ml epidermal growth factor (EGF), 7.5% NaHCO3 9 
and 10% heat-inactivated foetal bovine serum (FBS) in an atmosphere of 95% air and 5% 10 
CO2 in 95% relative humidity. The cell culture medium was changed every 2-3 days and cells 11 
between passages 28-33 were harvested at 80-90% confluency. HC11 cells were seeded at a 12 
density of 50,000 cells/cm
2
 in 6-well plates and cultured to confluency. Two days 13 
postconfluency cells were cultured for an additional 24 h in the FBS-containing RPMI 1640 14 
medium described above but without EGF. Differentiation of the HC11 cells was then 15 
achieved by culturing the cells for 72 h in EGF- and FBS-free RPMI 1640 medium 16 
supplemented with1 g/ml prolactin and 1 M cortisol as described (Desrivières et al., 2003). 17 
Undifferentiated HC11 cells (controls) were cultured in parallel with the FBS- and EGF-18 
containing RPMI 1640 medium. To study the cellular organization approximately 800,000 19 
cells in a volume of 400 l were seeded per chamber on slides (Lab-Tec® chamber slide™ 20 
system, Nalge Nunc International). In 4 of the 8 chambers on each slide (n=3) the cells were 21 
allowed to differentiate for 3 days as described above whereas the other 4 served as 22 
undifferentiated controls. The cells were fixed in 4°C acetone for 5 min and then rinsed with 23 
1XPBS, pH 7.4 prior to nuclei staining with hematoxylin. 24 
 25 
 7 
Quantitative real-time RT-PCR 1 
Following incubation of the HC11 cells in either control or differentiating culture medium as 2 
described above or transfection medium as described below the cells were rinsed with 1XPBS 3 
and the RNA was isolated by applying NucleoSpin
®
RNA II  Columns with DNaseI according 4 
to the instructions of the manufacturer (BD Biosciences). As a quality control of primers used 5 
in the real-time RT-PCR with cellular RNA, primers were tested on RNA from mouse 6 
mammary gland tissues taken at different lactation stages.  HARLAN NMRI-mice were given 7 
a standard pellet diet and tap water ad libitum under standard conditions of temperature and 8 
light. Animals were killed by cervical dislocation and mammary glands from pregnant 9 
(gestation days 13 and 18), lactating (lactation days 2 and 9) and weaning (weaning day 2) 10 
mice were rapidly excised, placed in RNAlater (Invitrogen), snap-frozen in liquid nitrogen 11 
and stored at -70°C pending isolation of total RNA. Tissues were homogenized in 10 volumes 12 
of RA1 buffer as recommended by the manufacturer (BD Biosciences) and RNA isolated with 13 
NucleoSpin
®
RNA II  Columns with DNaseI as described above. Animal experiments were 14 
ethically approved (permit no. 2012-15-2934-00587) and carried out in collaboration with Dr 15 
Christopher Knight, at the Department of Health and Medical Sciences, University of 16 
Copenhagen, Denmark. Total RNA from mammary glands was quantitated by use of the 17 
RiboGreen protocol with DNase I (Invitrogen) and RNA samples were stored at -70°C until 18 
used. Quantitative gene expression was measured by real-time RT-PCR by applying a 19 
Rotorgene, RG3000 (Corbett Research) as described (Öhrvik et al., 2010) in the presence of 20 
400 nM forward and reverse primers in a total volume of 12.5 l (Table 1).  21 
 22 
Western Blot 23 
HC11 cells were seeded at a density of 50,000 cells/cm
2
 in a total of 4 separate T75 tissue 24 
culture flasks and cultured and differentiated as described above prior to harvesting by 25 
 8 
trypsination and homogenization of the obtained cell pellet in 5 volumes of RIPA-lysis buffer. 1 
HC11 cells in 2 T75 flasks were differentiated as described above while the cells in the other 2 
2 flasks served as undifferentiated controls. The homogenization of the HC11 cells was 3 
carried out in 1.5 ml Eppendorf tubes by thorough pipetting. Homogenates were incubated on 4 
ice for 30 min and then centrifuged at 16,000Xg for 30 min at 4°C  and supernatant protein 5 
concentrations determined as described (McKie et al., 2000). 20-50 μg of cellular protein was 6 
separated on a 10% Tris-Glycine polyacrylamide gel under reducing conditions andblotted to 7 
nitrocellulose as described (Öhrvik et al., 2007). Three nitrocellulose membranes with 8 
proteins from each T75 flasks were incubated in blocking buffer (5% nonfat dry milk powder 9 
in Tris buffered saline containing 0.05% Tween 20 (TBS-T) over night at 4°C. Membranes 10 
were then hybridized with a primary BCRP antibody (BXP-53, Abcam) diluted 1:100 or 11 
primary MDR1 antibody (JSB-1, Abcam) diluted 1:200 in TBS-T. The primary antibodies 12 
were detected by Horse Radish Peroxidase-conjugated secondary antibodies (ab6728, Abcam) 13 
diluted 1:7500 in TBS-T. In order to normalize the intensities of the bands, all the membranes 14 
were stripped at 60°C with buffer containing 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol, 15 
2% SDS and then hybridized with anti-Tubulin antibody (YOL1/34) diluted 1:3000. Horse 16 
Radish Peroxidase-conjugated secondary antibodies to tubulin (ab6734, Abcam) diluted 17 
1:5000 in TBS-T. HRP was detected by ECL Advance (GE Healthcare) and the intensities of 18 
the obtained bands quantitated as described (Öhrvik et al. 2010). As a quality control of the 19 
antibodies used in the Western with cellular protein, they were tested on protein isolated from 20 
mammary gland of pregnant and lactating mice. 21 
 22 
Bcrp RNAi 23 
Prior to the Bcrp RNAi of the HC11 cells optimization of transfection efficiency was 24 
performed by incubating various densities of HC11 cells with either siTOX Transfection 25 
 9 
Control (Dharmacon) or a non-targeting negative control (On-Target plus siControl Non-1 
Targeting Pool, Dharmacon) in the presence of various dilutions of DharmaFECT siRNA 2 
Transfection Reagents 1-4, as recommended by the manufacturer (Dharmacon). ATP levels 3 
were measured to check viability of the HC11 cells following each set of transfection 4 
condition by applying the ATP Determination Kit (Invitrogen), with formaldehyde-treated 5 
cells as positive controls. Firefly luciferase induced chemiluminescence of cellular ATP was 6 
measured on a Victor
2
 1420 multilabel counter (PerkinElmer). Following the various 7 
transfection conditions the one resulting in the lowest viability following treatment with 8 
siTOX Transfection Control reagent and the highest viability following treatment with the 9 
On-Target plus siControl Non-Targeting Pool was selected. Following this optimization of 10 
transfection efficiency cyclophilin B siRNA transfection was performed under the optimized 11 
condition by the use of siControl cyclophilin B siRNA (targeting mouse cyclophilin, 12 
accession number NM_011149) according to the instructions of the manufacturer. The 13 
silencing of the cyclophilin B gene was measured by quantitative real-time RT-PCR with 14 
specific primers (Table 1) as described above. After successful silencing of cyclophilin B the 15 
optimized siRNA transfection protocol was adopted to silence Bcrp expression. HC11 cells 16 
were harvested in antibiotic-free RPMI 1640 medium and seeded into 6-well tissue culture 17 
plates at a density of 8,300 cells/cm
2
. After incubation for 24 h at 37
◦
C the medium was 18 
replaced with 2 ml of transfection medium (Opti-MEM) containing 100 nM On-Target plus 19 
SMART pool (targeting mouse BCRP, accession number NM_011920) and DharmaFECT 1 20 
Transfection Reagent diluted 1:4. Mock transfected cells were incubated as described above 21 
with 2 ml Opti-MEM containing 100 nM On-Target plus siControl Non-Targeting RNA 22 
duplexes. Following transfection for 48 h at 37
◦
C the HC11 cells were either subjected to 23 
RNA isolation for quantitative gene expression of Bcrp by real-time RT-PCR or transport 24 
experiments with MX (as described below). 25 
 10 
 1 
Transport experiments 2 
Prior to the experiments HC11 cells were seeded in 12 well plates at a density of 50,000 3 
cells/cm
2
 and cultured and treated as described above. MX (Sigma) was used to examine the 4 
function of BCRP in the HC11 cells using 
3
H-MX, with a specific radioactivity of 4 Ci/mmol, 5 
as tracer (Moravek Biochemicals). It has previously been demonstrated that BCRP mediated 6 
transport of MX is reduced by GF120918 (de Bruin et al., 1999). Accumulation studies with 7 
MX were performed as follows. HC11 cells were rinsed with 2 x 1.5 ml of 37ºC Hank’s 8 
Balanced Salt Solution with CaCl2 and MgCl2 (Invitrogen), pH 7.4 containing 25 mM N-(2-9 
hydroxyehtyl) piperazine-N’-(2-ethanesulfonic) acid (HEPES, Sigma-Aldrich) (HBSS) and 10 
then pre-incubated for 30 min at 37º in 1.5 ml HBSS. After pre-incubation the HC11 cells 11 
were incubated at 37ºC for 60 min with 37ºC HBSS containing 1 M MX supplemented 3000 12 
Bq 
3
H-MX/ml. Experiments including inhibitor were performed in HBSS, containing 1 M of  13 
GF120918 during the 60 min incubation period. At the end of theexperiment the HC11-cells 14 
were rinsed with 3 x 1.5 ml ice-cold HBSS and thereafter lysed by adding 1 ml 0.5 M NaOH 15 
to each well. The MX concentration in the HC11 cells was then calculated from the 16 
radioactivity measurement by -spectrometry using a 1900 CA Tri-Carb®Liquid Scintillation 17 
Analyzer (Packard Instruments). An aliquot of the cell lysate was used for protein 18 
determination by applying the BCA-method (as described above). 19 
 20 
To study secretion of MX HC11 cells were preincubated as described above and then 21 
incubated with 1 M MX supplemented 3000 Bq 3H-MX/ml at 37ºC for 60 min. After this 22 
loading period the incubation medium was discarded and the HC11 cells were rinsed with 2 x 23 
1.5 ml 37ºC HBSS. After the washes 1.5 ml of  37ºC HBSS with or without 1 M GF120918 24 
was added to the wells followed by incubation at 37ºC for 45 min. At the end of the secretion 25 
 11 
experiment the HBSS was sampled and MX concentrations measured by -spectrometry as 1 
described above. Both accumulation and secretion of MX was normalized to total cellular 2 
protein of the HC11 cells. Prior to the transport experiments potential cellular toxicity of the 3 
MX and GF120918 was assessed by measuring cellular ATP levels as described above or 4 
leakage of lactate dehydrogenase (LDH) as described previously (Aspenström-Fagerlund et 5 
al., 2007). No effects in ATP- or LDH-levels were detected in the experimental conditions 6 
and MX and GF120918 concentrations used in the present study indicating that the observed 7 
effects in accumulation and secretion were not a result of cytotoxicity induced by of these 8 
chemical compounds.  9 
 10 
Statistics 11 
Statistical analysis was performed using Statview 4.1 software for PC. Kruskal-Wallis was 12 
used to detect any significant differences in the data. Mann-Whitney was applied to examine 13 
statistically significant differences between two groups. The level of significance was set at p 14 
≤ 0.05. 15 
16 
 12 
Results 1 
 2 
Cellular organization 3 
The morphology of the HC11 cells was affected by the differentiation procedure. The 4 
differentiated cells showed a characteristic pattern with alveolar resembling structures 5 
including lumina, whereas the undifferentiated cells were organized as a monolayer (Figure 6 
1). 7 
 8 
mRNA expressions 9 
Gene expression of -casein (Csn2) and Bcrp was detected in both undifferentiated and 10 
differentiated HC11 cells. A statistically significant induction of -casein gene expression 11 
was observed in the differentiated HC11 cells as compared to the undifferentiated controls 12 
(Figure 1a). Thus, the relative -casein gene expression was increased 2-fold in the 13 
differentiated as compared to the undifferentiated HC11 cells (Figure 1a). The relative Bcrp 14 
gene expression was at a similar level in undifferentiated and differentiated HC11 cells 15 
(Figure 2a). A statistically significant 2-fold reduction in Mdr1 gene expression was observed 16 
in the differentiated HC11 as compared to the undifferentiated ones (Figure 2b).  17 
 18 
Protein expressions 19 
Bcrp and Mdr1-protein was detected in both undifferentiated and differentiated HC11 cells 20 
(Figure 3). Tubulin normalized Bcrp protein expression was up-regulated and Mdr1 protein 21 
expression down-regulated in the differentiated as compared to the undifferentiated HC11 22 
cells (Figure 3). Quantification of Bcrp and Mdr1 protein levels in differentiated and 23 
undifferentiated HC11 cells as performed in two separate experiments with triplicate analyses 24 
did not show any overlaps in protein levels. 25 
 13 
  1 
Bcrp silencing 2 
To test the function of our optimized transfection efficiency conditions RNAi was initially 3 
performed with the house-keeping gene cyclophilin B. Our results showed that almost a 90% 4 
down-regulation of the cyclophilin B gene expression was obtained (Figure 4). Using the 5 
same protocol with Bcrp siRNA-duplexes Bcrp-transcript levels were reduced to the same 6 
extent as cyclophilin (Figure 4). 7 
  8 
Transport experiments 9 
The transport experiments with 
3
H-MX showed that the accumulation was increased in both 10 
undifferentiated and differentiated HC11 cells simultaneously incubated with GF120918 11 
(Figure 5a). Thus, in the presence of the BCRP inhibitor the accumulation of MX increased 12 
with about 21% in the undifferentiated HC11 cells and with about 36% in the differentiated 13 
ones. Our results also showed that the accumulation of MX was higher in the differentiated 14 
HC11 cells as compared to the undifferentiated controls (Figure 5a). The presence of the 15 
inhibitor GF120918 also resulted in a decreased secretion of MX from the loaded HC11 cells 16 
(Figure 5b). The secretion of MX was reduced to about 65% in the presence of GF120918 in 17 
undifferentiated HC11 cells and to about 70% in the differentiated ones. The results obtained 18 
in the transport experiments with 
3
H-MX showed that the accumulation of MX in HC11 cells 19 
increased 2-fold by Bcrp RNAi as compared to the MX accumulation in the mock transfected 20 
HC11 cells (Figure 5a). 21 
22 
 14 
Discussion 1 
 2 
The results obtained in the present investigation demonstrate for the first time that both Bcrp 3 
and Mdr1 are expressed in the HC11 cells and are up- and downregulated, respectively by 4 
differentiation  as in mammary epithelial cells in vivo during lactation. Thus, whereas Bcrp 5 
protein levels were increased in HC11 cells differentiated into a secreting phenotype, Mdr1 6 
protein levels were decreased. These results are in line with the in vivo findings that BCRP is 7 
up-regulated and MDR1 down-regulated in lactating mammary glands in various species 8 
(Alcorn et al., 2002; Jonker et al., 2005; Gilchrist and Alcorn, 2009) and suggest that the 9 
HC11 model can be used to both assess function of endogenous Bcrp and to detect new 10 
substrates as well as inducers and inhibitors of this transporter.  11 
 12 
HC11 cells have been used as a model for studies on hormonal regulation of mammary 13 
epithelial cell differentiation as well as milk protein gene expression and secretion (Wartmann 14 
et al., 1996; Desrivières et al., 2003; Kabotyanski et al., 2006). Furthermore, HC11 cells have 15 
been applied to examine the impact of toxic compounds on lactating mammary cells (Öhrvik 16 
et al., 2010) and also to characterize some transporters belonging to the Solute Carrier (SLC) 17 
family and ion channels, which are implicated in the flux of magnesium, zinc, copper and 18 
calcium across the membranes of the lactating mammary epithelium (Kelleher and Lönnerdal, 19 
2005, 2006; Boyd and Náray-Fejes-Tóth, 2007; Öhrvik et al, 2010; Wolf et al., 2010; 20 
McCormick and Kelleher, 2012; Ross et al., 2013). However, the HC11 cell model has not yet 21 
been used to characterize expression and/or function of ATP Binding Cassette (ABC) 22 
transporters. The localization of both BCRP and MDR1 in the apical membranes of MECs in 23 
combination with the promiscuity of these active transporters has risen considerable concern 24 
from public health, food safety, and regulatory perspectives about the presence of drugs and 25 
 15 
toxic compounds in milk both for breast fed infants as well as for consumers of dairy products 1 
(Wassermann et al., 2013).     2 
 3 
Herein, we showed that Bcrp gene expression was at a similar level in undifferentiated and 4 
differentiated HC11 cells whereas Mdr1 transcript levels were reduced in the differentiated 5 
ones. The reason for the lack of induction of Bcrp mRNA in the HC11 cells by lactogenic 6 
stimulation in the present investigation is unknown. However, one possible explanation may 7 
be that the HC11 cells originally derive from mammary tissue of BALB/c mice during 8 
gestation when Bcrp transcripts levels are induced to a stage where no further increases in 9 
gene expression occurs (Danielsson et al., 1984; Jonker et al., 2005). In support of this, 10 
silencing of Bcrp gene expression in undifferentiated HC11 cells resulted in a marked 11 
decrease in Bcrp function as assessed by increased MX accumulation, which probably would 12 
not have been possible to demonstrate if the endogenous Bcrp expression in the control cells 13 
was at a baseline level. 14 
 15 
In the present investigation the HC11 cells differentiated by treatment with prolactin and 16 
cortisol were organized into alveolar-like structures with lumina resembling the organization 17 
of the mammary epithelial cells observed in the mammary glands in vivo during lactation 18 
(Burgoyne and Duncan, 1998; Richert et al., 2000).. Beside the changes in cellular 19 
organization by lactogenic stimulation -casein gene expression was also induced in the 20 
HC11 cells. It has previously been demonstrated that -casein responds to prolactin in HC11 21 
cells (Ball et al., 1988) and that synthesis occurs in rodent MEC in vivo and that the 22 
abundance of this milk protein increases during gestation and peaks at mid-lactation 23 
(Robinson et al., 1995; Burgoyne and Duncan, 1998; Richert et al., 2000; McManaman and 24 
Neville, 2003). Thus, reorganization of HC11 cells into alveolar-resembling formations in 25 
 16 
combination with an increased -casein gene expression by lactogenic stimulation appears to 1 
be reliable markers of a secreting phenotype. Based on the results obtained in the present 2 
study reduced gene and protein expression of Mdr1 as well as increased expression of Bcrp 3 
protein may also be used as secretory markers of the HC11 cells. 4 
 5 
Our results showed that the net accumulation of MX was higher in the differentiated HC11 6 
cells as compared to the undifferentiated controls despite an apparent higher expression of 7 
Bcrp. This may, at least in part, be explained by a reduced expression of Mdr1. Although MX 8 
extrusion is predominantly mediated by Bcrp it has been demonstrated that MX can be 9 
transported to the extracellular compartment by Mdr1 although this transporter harbors less 10 
substrate specificity for MX than Bcrp and thus requires higher substrate concentrations 11 
(Ahmed-Belkacem, 2005; Rautio et al., 2006; Kodaira et al., 2010). Numerous SLC 12 
transporters, comprising both organic cation transporters (OCTs) and organic anion 13 
polypeptide transporters (OATPs), in MECs are affected at the transcriptional level by 14 
lactogenic stimulation (Alcorn et al., 2002; Gilchrist and Alcorn, 2010) including some with 15 
potential MX affinity. It may, hence, be possible that the increased accumulation of MX in the 16 
HC11 cells featuring a secretory phenotype as opposed to the undifferentiated ones is not only 17 
connected to the reduced expression of Mdr1 observed herein, but also to a concerted action 18 
of a number of other transporters including  Oct or/and Oatp transporters.  19 
 20 
Madine-Darby Canine Kidney II (MDCK II), human intestinal epithelial cells (Caco-2), 21 
human breast adenocarcinoma cells (MCF7), human choriocarcinoma cells (BeWo) and 22 
human bone osteosarcoma cells (SAOS-2) constitute examples of models used to characterize 23 
the function and substrate specificities of efflux proteins such as BCRP (Doyle et al., 1998; 24 
Jonker et al., 2000; Ceckova et al., 2006; Matsson et al., 2007; Li et al., 2011; Wasserman et 25 
 17 
al., 2013). However, cancer cell lines and non-tumorigenic cell lines deriving from tissues 1 
other than the alveolar lining of the mammary glands harbor different sets of transporter 2 
protein panels at both the apical and basolateral membranes which may affect secretion and 3 
net accumulation of substrates may therefore differ (Krajci 2013). As expected by a Bcrp 4 
inhibitor, GF120918 treatment of HC11 cells decreased both net accumulation and secretion 5 
of MX. This corroborates our suggestion that the HC11 cells can be used for assessing 6 
transport of potential Bcrp substrates across the mammary epithelium. 7 
 8 
The results obtained in the present investigation demonstrate for the first time that the murine 9 
mammary epithelial HC11 cells feature endogenous Bcrp and Mdr1 expression and that the 10 
expressions of these transporter proteins appear to respond to treatment with lactogenic 11 
hormones in a corresponding manner as mammary epithelial cells in vivo during lactation. 12 
Based on these findings it can be concluded that the HC11cells comprise a promising tool to 13 
assess the impact of drugs and other chemicals on endogenous BCRP function.  14 
 15 
 16 
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Table 1. Exon-spanning oligonucleotide primers used for quantitative gene expression 1 
analyses by real-time RT-PCR. 2 
 3 
Gene Primer Sequences 
-casein 5’-CTTAACCCCACCGTCCAAT-3’ (forward) 
5’-AGCATGATCCAAAGGTGAAAA-3’ (reverse) 
Bcrp/Abcg2 5’-CGCAGAAGGAGATGTGTT-3’ (forward) 
5’-TTGGATCTTTCCTTGCTGCT-3’ (reverse) 
Mdr1/Abcb1 
 
5’-GCTGTTAAGGAAGCCAATGC-3’ (forward) 
5’-AGCAATGGCGATTCTCTGGTT-3’ (reverse) 
Cyclophilin B 5’-GCGCAATATGAAGGTGCTCT-3’ (forward) 
5’-GAAGTCTCCACCCTGGATCA-3’ (reverse) 
 4 
5 
 28 
Legends to the figures 1 
 2 
Figure 1. a. Cellular organization of undifferentiated and differentiated HC11 cells as 3 
described in Materials and Methods. Undifferentiated HC11 cells not stimulated with 4 
lactogenic hormones are organized as monolayers (left). Differentiated cells treated with 5 
prolactin and hydrocortisone are formatted in alveolar-resembling structures with alveolar 6 
lumina (right). b. Relative -casein gene expression in undifferentiated and differentiated 7 
HC11 cells, as described in Materials and Methods. The data are presented as means ± SD of 8 
6 samples from 2 separate experiments. *Statistically significant different as compared to 9 
undifferentiated controls, p ≤ 0.05. 10 
 11 
Figure 2. Relative gene expression of Bcrp (a) and Mdr1 (b) in undifferentiated and 12 
differentiated HC11 cells, as described in Materials and Methods. The data are presented as 13 
means ± SD of 6 samples from 2 separate experiments. *Statistically significant different as 14 
compared to undifferentiated controls p ≤ 0.05.  15 
 16 
Figure 3. Protein expression of BCRP (a) and MDR1 (b) in undifferentiated and 17 
differentiated HC11 cells, normalized to tubulin expression as described in Materials and 18 
Methods. The data represent BCRP and MDR1 protein expression in HC11 cell lysates 19 
obtained in two separate experiments, each comprising three membranes per protein 20 
expressed as relative means and ranges. 21 
 22 
Figure 4. Relative gene expressions of cyclophilin B and Bcrp in HC11 cells subjected to 23 
RNA interference (RNAi).   The data are presented as means ± SD of 3-5 samples obtained 24 
from 2 separate experiments. 
*
Statistically significant as compared to untransfected controls 25 
 29 
(Opti-MEM) and mock transfected cells (Opti-MEM containing Lipid 1 diluted 1:4 and non-1 
targeting RNA duplexes) as described in Materials and Methods, p ≤ 0.05. 2 
 3 
Figure 5. Accumulation (a) and secretion (b) of 
3
H-mitoxantrone in undifferentiated (No) or , 4 
differentiated (Yes) HC11 cells,  treated with the BCRP inhibitor GF120918, and in mock 5 
transfected (mock) and  Bcrp RNAi treated (Bcrp RNAi) HC11 cells, as described in Material 6 
and Methods. The data are presented as means ± SD of 6-12 samples and expressed as pmol 7 
mitoxantrone/mg cellular protein as described in Materials and Methods.  Statistically 8 
significant differences between groups are indicated by links between the columns (*p ≤ 0.05; 9 
**p ≤ 0.01). 10 
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